Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Halozyme Therapeutics Inc (NASDAQ: HALO) closed at $68.3 up 0.37% from its previous closing price of $68.05. In other words, the price has increased by $0.37 from its previous closing price. On the day, 1.49 million shares were traded. HALO stock price reached its highest trading level at $70.49 during the session, while it also had its lowest trading level at $67.8.
Ratios:
For a deeper understanding of Halozyme Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.33. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.59. In the meantime, Its Debt-to-Equity ratio is 3.00 whereas as Long-Term Debt/Eq ratio is at 1.59.
On August 06, 2025, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $75.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 01 ’25 when Torley Helen sold 20,000 shares for $75.35 per share. The transaction valued at 1,507,024 led to the insider holds 733,719 shares of the business.
Torley Helen sold 20,000 shares of HALO for $1,424,083 on Oct 02 ’25. The PRESIDENT AND CEO now owns 733,719 shares after completing the transaction at $71.20 per share. On Oct 03 ’25, another insider, Torley Helen, who serves as the PRESIDENT AND CEO of the company, sold 20,000 shares for $69.03 each. As a result, the insider received 1,380,638 and left with 733,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 8031875584 and an Enterprise Value of 8868769792. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.36, and their Forward P/E ratio for the next fiscal year is 8.40. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.46 while its Price-to-Book (P/B) ratio in mrq is 15.93. Its current Enterprise Value per Revenue stands at 7.136 whereas that against EBITDA is 10.905.
Stock Price History:
The Beta on a monthly basis for HALO is 0.95, which has changed by 0.14082146 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $79.50, while it has fallen to a 52-week low of $42.01. The 50-Day Moving Average of the stock is -3.60%, while the 200-Day Moving Average is calculated to be 10.44%.
Shares Statistics:
For the past three months, HALO has traded an average of 2.09M shares per day and 1594400 over the past ten days. A total of 117.52M shares are outstanding, with a floating share count of 116.30M. Insiders hold about 1.10% of the company’s shares, while institutions hold 101.19% stake in the company. Shares short for HALO as of 1760486400 were 11510110 with a Short Ratio of 5.50, compared to 1757894400 on 11779854. Therefore, it implies a Short% of Shares Outstanding of 11510110 and a Short% of Float of 13.74.
Earnings Estimates
The stock of Halozyme Therapeutics Inc (HALO) is currently in the spotlight, with 6.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $1.69, with high estimates of $1.99 and low estimates of $1.53.
Analysts are recommending an EPS of between $6.39 and $5.46 for the fiscal current year, implying an average EPS of $6.12. EPS for the following year is $7.91, with 5.0 analysts recommending between $9.02 and $7.17.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $395.21M this quarter.It ranges from a high estimate of $417M to a low estimate of $378M. As of. The current estimate, Halozyme Therapeutics Inc’s year-ago sales were $298.01MFor the next quarter, 7 analysts are estimating revenue of $378.77M. There is a high estimate of $399.07M for the next quarter, whereas the lowest estimate is $362.23M.
A total of 9 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $1.36B, while the lowest revenue estimate was $1.31B, resulting in an average revenue estimate of $1.33B. In the same quarter a year ago, actual revenue was $1.02BBased on 7 analysts’ estimates, the company’s revenue will be $1.68B in the next fiscal year. The high estimate is $1.79B and the low estimate is $1.57B.
